Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Joshua Ryan Richter, Thomas G. Martin, Ravi Vij, Craig Cole, Djordje Atanackovic, Jeffrey A. Zonder, Jonathan L. Kaufman, Joseph Mikhael, William Bensinger, Meletios A. Dimopoulos, Todd M. Zimmerman, Nikoletta Lendvai, Parameswaran Hari, Enrique M. Ocio, Cristina Gasparetto, Shaji Kumar, Corina Oprea, Eric Charpentier, Stephen Anthony Strickland, Jesus San Miguel
Institutions: Hackensack University Medical Center, University of California, San Francisco, Washington University in St. Louis, University of Michigan, U-M Rogel Cancer Center, Huntsman Cancer Institute, The Barbara Ann Karmanos Cancer Institute, Emory University, Winship Cancer Institute, Mayo Clinic in Arizona, Fred Hutch Cancer Center, National and Kapodistrian University of Athens, University of Chicago, Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin, Universidad de Salamanca, Duke Medical Center, Mayo Clinic, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Universidad de Navarra
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891637788